Literature DB >> 8390451

COOH-terminal amino acids of the alpha subunit play common and different roles in human choriogonadotropin and follitropin.

J Yoo1, H Zeng, I Ji, W J Murdoch, T H Ji.   

Abstract

Human choriogonadotropin (hCG) and follitropin (FSH) belong to the glycoprotein hormone family. These hormones are heterodimers and composed of a common alpha subunit and a distinct beta subunit which confers receptor-binding specificities. In addition to this structural similarity, they share a similar signal pathway involving G protein, adenylyl-cyclase and induction of cAMP synthesis. Therefore, a presumptive relationship of these common structure and function has been the subject of extensive past investigations, but a definitive clue has been elusive. As a step to address this important issue, a series of recombinant mutants of hCG and human FSH were generated in which the COOH-terminal amino acids of the alpha subunit were successively removed or substituted. Furthermore, a set of peptides were synthesized with sequences corresponding to different regions of the alpha subunit. Deletion of the alpha COOH-terminal Ser92 had no effect on receptor-binding or cAMP induction by FSH and hCG. Truncation of alpha Lys91-Ser92 or alpha His90-Lys91-Ser92 abolished the ability of both hormones to induce cAMP synthesis. It significantly reduced receptor binding of FSH but not hCG. The different functions of the alpha COOH-terminal region are further noticed with a peptide corresponding to the last 10 amino acids of alpha. It failed to bind to the FSH receptor but was capable of binding to the LH/CG receptor and stimulating cAMP synthesis. These results are the first conclusive evidence that alpha His90-Lys91 play an essential role in cAMP induction of both hormones. In contrast to this common role, they are necessary for FSH binding to the FSH receptor but not for hCG binding to the LH/CG receptor. The hCG alpha COOH-terminal region makes direct contact with the LH/CG receptor, and this low affinity contact is necessary and sufficient to activate the receptor for signal generation. This conclusion is supported by the study using mutant hCGs in which either alpha His90 or Lys91 was substituted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390451

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Receptor binding dependent structural changes in human choriogonadotropin: photochemical inter-subunit crosslinking.

Authors:  I Ji; Y N Pan; Y M Lee; T Phang; T H Ji
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

2.  Activation of membrane receptors.

Authors:  T H Ji; W J Murdoch; I Ji
Journal:  Endocrine       Date:  1995-03       Impact factor: 3.633

3.  Assembly and structural characterization of an authentic complex between human follicle stimulating hormone and a hormone-binding ectodomain of its receptor.

Authors:  Qing R Fan; Wayne A Hendrickson
Journal:  Mol Cell Endocrinol       Date:  2006-10-12       Impact factor: 4.102

4.  The antibodies against the computationally designed mimic of the glycoprotein hormone receptor transmembrane domain provide insights into receptor activation and suppress the constitutively activated receptor mutants.

Authors:  Ritankar Majumdar; Reema Railkar; Rajan R Dighe
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

5.  Functional differences of invariant and highly conserved residues in the extracellular domain of the glycoprotein hormone receptors.

Authors:  Krassimira Angelova; Hugo de Jonge; Joke C M Granneman; David Puett; Jan Bogerd
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

6.  Human alpha-subunit analogs act as partial agonists to the thyroid-stimulating hormone receptor: differential effects of free and yoked subunits.

Authors:  Krassimira Angelova; Valerie Fremont; Renita Jain; Meng Zhang; David Puett; Prema Narayan; Mariusz W Szkudlinski
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.